In this respect, chronic DYRK1A inhibition ameliorated cognitive impairments in an AD mouse model and furthermore resulted in decreased APP phosphorylation, reduction of Aβ production, and Tau phosphorylation in the insoluble fragment, while NFT pathology remained unaltered [195,196]. This evidence concerns the gene MAPT and Alzheimer disease.